adenocarcinoma of the lung


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

adenocarcinoma

 [ad″ĕ-no-kahr″sĭ-no´mah]
carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures. The World Health Organization recognizes four categories of adenocarcinoma: acinar, papillary, bronchioalveolar, and solid carcinoma with mucus formation; it can be further subclassified into well, moderate, and poorly differentiated forms.
alveolar adenocarcinoma (bronchioalveolar adenocarcinoma) (bronchiolar adenocarcinoma) (bronchioloalveolar adenocarcinoma) (bronchoalveolar adenocarcinoma) bronchioloalveolar carcinoma.
clear cell adenocarcinoma a rare malignant tumor of the female genital tract, resembling a renal cell carcinoma and containing tubules or small cysts with some cells that are hobnail-shaped and others whose cytoplasm is clear, containing abundant glycogen and inconspicuous stroma. It may occur in the ovary, uterus, cervix, or vagina. One form has been linked to in utero exposure to diethylstilbestrol. Called also clear cell carcinoma and mesonephroma.
adenocarcinoma of the lung a type of bronchogenic carcinoma made up of cuboidal or columnar cells in a discrete mass, usually at the periphery of the lungs.

adenocarcinoma of the lung

a type of bronchogenic carcinoma made up of a discrete mass of cuboidal or columnar epithelial cells, generally at the lung periphery. Most of these tumors form glandular structures that contain mucin, although a few lack mucin and are solid. Growth is slow, but there may be early invasion of blood and lymph vessels by metastases while the primary lesion is still asymptomatic. There are two types of lung adenocarcinomas: bronchioloalveolar carcinoma and bronchogenic adenocarcinoma.
References in periodicals archive ?
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Mutational activation of the K-ras oncogene; a possible pathogenetic factor in adenocarcinoma of the lung.
It is estimated that about three-quarters of adenocarcinoma of the lung are FRA-positive.
A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2).
First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
In LUX-Lung 2, a Phase 2 study, 444 patients with advanced adenocarcinoma of the lung who were untreated or progressed after one course of chemotherapy were tested for common EGFR mutations.
KIF5B/RET fusion gene in surgically treated adenocarcinoma of the lung [published online ahead of print July 13, 2012].
Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung.
BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).